scholarly journals COVID-19 and Thrombotic Thrombocytopenic Purpura: A Case Report

2021 ◽  
Author(s):  
Maryam Darnahal ◽  
Hamed Azhdari Tehrani ◽  
Mohammad Vaezi ◽  
Shirin Haghighi
Keyword(s):  
Case Report ◽  
Blood Cell ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Organ Dysfunction ◽  
Red Blood Cell ◽  
Immune Complexes ◽  
Cell Injury ◽  
Coagulation Cascade ◽  
Thrombotic Microangiopathies ◽  
Thrombocytopenic Purpura

Endothelial injury by toxins, drugs, immune complexes leads to activation of coagulation cascade and thrombosis, which result in platelet consumption and red blood cell injury. These thrombotic microangiopathies can potentially injure numerous organs and result in organ dysfunction. In this case, we present the fourth reported patient with thrombotic thrombocytopenic purpura associated with COVID-19.

Effectiveness of bortezomib in the treatment of thrombotic thrombocytopenic purpura: Case report

2019 ◽  
Vol 152 (6) ◽  
pp. 244-245
Author(s):  
Eva Hernández Lorente ◽  
Rafael Lluch García ◽  
Emilio Monteagudo Santolaya
Keyword(s):  
Case Report ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Thrombocytopenic Purpura

scholarly journals Current insights into thrombotic microangiopathies: Thrombotic thrombocytopenic purpura and pregnancy

2015 ◽  
Vol 135 ◽  
pp. S30-S33 ◽  
Author(s):  
Charis von Auer ◽  
Anne-Sophie von Krogh ◽  
Johanna A. Kremer Hovinga ◽  
Bernhard Lämmle
Keyword(s):  
Thrombotic Thrombocytopenic Purpura ◽  
Thrombotic Microangiopathies ◽  
Thrombocytopenic Purpura

scholarly journals An Early Unexpected Immune Thrombotic Thrombocytopenic Purpura Relapse Associated with SARS-CoV-2 Infection: A Case Report and Literature Review

2021 ◽  
pp. 1-5
Author(s):  
Maya Kornowski Cohen ◽  
Liron Sheena ◽  
Yair Shafir ◽  
Vered Yahalom ◽  
Anat Gafter-Gvili ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Case Report ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Lupus Erythematosus ◽  
Response To Therapy ◽  
Intravascular Hemolysis ◽  
Systemic Lupus ◽  
Thrombocytopenic Purpura ◽  
History Of ◽  
Triggering Factor

SARS-CoV-2 has been reported as a possible triggering factor for the development of several autoimmune diseases and inflammatory dysregulation. Here, we present a case report of a woman with a history of systemic lupus erythematosus and antiphospholipid syndrome, presenting with concurrent COVID-19 infection and immune thrombotic thrombocytopenic purpura (TTP). The patient was treated with plasma exchange, steroids, and caplacizumab with initial good response to therapy. The course of both TTP and COVID-19 disease was mild. However, after ADAMTS-13 activity was normalized, the patient experienced an early unexpected TTP relapse manifested by intravascular hemolysis with stable platelet counts requiring further treatment. Only 3 cases of COVID-19 associated TTP were reported in the literature thus far. We summarize the literature and suggest that COVID-19 could act as a trigger for TTP, with good outcomes if recognized and treated early.

Abdominal wall hematomata and colonic tumor detected on labeled red blood cell scintigraphy: case report

2003 ◽  
Vol 17 (5) ◽  
pp. 399-402
Author(s):  
S. Angelides ◽  
M. G. Gibson ◽  
J. Kurtovic ◽  
S. Riordan
Keyword(s):  
Case Report ◽  
Blood Cell ◽  
Abdominal Wall ◽  
Red Blood Cell ◽  
Colonic Tumor
Sign in / Sign up

Export Citation Format

Share Document